PHT Corporation, the US-based provider of electronic patient-reported outcomes (ePRO) and electronic clinical outcome assessment (eCOA) solutions for data collection in clinical trials, has reported increases of 25% in revenues and global headcount for 2012.
The company attributed its fourth consecutive year of profitable growth to regulators and pharmaceutical executives recognising the scientific and business benefits of leveraging patient-driven eData in clinical research.
For example, adoption of NetPRO, PHT’s web-based system for collecting patient and clinician data, doubled last year. And there was continued strong demand for the SitePad System which captures patient-reported outcomes and clinical data at the investigation site, the company said.
PHT has also implemented more than 600 eCOA systems for 145 trial sponsors around the world.
Most of the headcount expansion during 2012 was in client services, customer support, engineering and consulting services.
Last year’s revenue increase bolstered PHT’s market share of 40%, the company noted. Partnerships with contract research organisations (CROs), which accounted for 20% of all bookings, helped to drive the revenue gains, while PHT added nine new clients through direct sales.
Another growth factor, PHT added, is that sponsors and CROs are leveraging the company’s ePRO and eCOA systems for a broader range of indications and therapeutic areas, including rheumatoid arthritis, haemophilia, diabetes and psoriasis.
This was in addition to oncology and a number of central nervous system indications, such as schizophrenia and Alzheimer’s disease.